Therapeutic Advances in Endocrinology and Metabolism

Papers
(The H4-Index of Therapeutic Advances in Endocrinology and Metabolism is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Controversies in the management of active Charcot neuroarthropathy104
Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review76
In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity52
Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis32
Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults25
Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging – a narrative review23
Differences in adherence to using removable cast walker treatment during daytime and nighttime weight-bearing activities in people with diabetes-related foot ulcers21
The global burden of thyroid cancer in high-income Asia-Pacific: a systematic analysis of the Global Burden of Disease study21
Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system20
Update on genetics and epigenetics in metabolic associated fatty liver disease20
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease18
Pheochromocytoma: a changing perspective and current concepts17
Novel therapeutic targets for metabolism-related diseases: proteomic Mendelian randomization and colocalization analyses17
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor16
Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus16
Is there a causal relationship between hypothyroidism and hyponatremia?16
0.23332405090332